Anixa Biosciences, Inc.
Company Snapshot: Anixa Biosciences, Inc.
Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.anixa.com.
- Sep 19 2019 Anixa Biosciences Commences Collaboration with Potomac Urology Center on Cchek™ Prostate Cancer Study
- Sep 16 2019 Anixa Biosciences Congratulates Scientific Advisory Board Member Dr. H. Michael Shepard as a 2019 Lasker Award Honoree
- Aug 26 2019 Anixa Biosciences to Present at Two Upcoming Investor Conferences
- Jul 29 2019 Anixa Biosciences Announces VA North Texas Health Care System to Join Cchek™ Prostate Cancer Study